Polyomavirus Bk Infection in Pediatric Kidney-

patients. Am J Transplant 2001; 1: 385 (A 991). 12. Niemeyer G, Koch M, Light S, et al. Long-term safety, tolerability and efficacy of daclizumab (Zenapax) in a two-dose regimen in liver transplant recipients. Am J Transplant 2002; 2: 454. 13. Gaber AO, Gaber LW, Shokouh-Amiri MH, et al. Percutaneous biopsy of pancreas transplants. Transplantation 1992; 54: 548. 14. Nashan B, Light S, Hardie IR, et al. Reduction of acute renal allograft rejection by daclizumab. Daclizumab double therapy study group. Transplantation 1999; 67: 110. 15. Solez K, Axelsen RA, Benediksson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411. 16. Papadimitriou JC, Drachenberg CB, Wiland A, et al. Histologic grading of acute allograft rejection in pancreas needle biopsy. Transplantation 1998; 66: 1741. 17. Bruce DS, Sollinger HW, Humar A, et al. Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients. Transplantation 2001; 72: 1637. 18. Bruce DS, Woodle ES, Newell KA, et al. Tacrolimus/mycophenolate mofetil provides superior immunosuppression relative to Neoral/mycophenolate in synchronous pancreas-kidney transplantation. Transplant Proc 1998; 30: 1538. 19. Burke GW, Ciancio G, Alejandro R, et al. Use of tacrolimus and mycophenolate mofetil for pancreas-kidney transplantation with or without OKT3 induction. Transplant Proc 1998; 30: 1544. 20. Corry RJ, Shapiro R, Egidi MF, et al. Pancreas transplantation without antibody therapy. Transplant Proc 1998; 30: 299. 21. Gruessner RWG, Sutherland DER, Drangstveit MF, et al. Mycophenolate mofetil and tacrolimus for induction and maintenance therapy after pancreas transplantation. Transplant Proc 1998; 30: 518. 22. Kaufman DB, Burke G, Bruce D, et al. The role of antibody induction in simultaneous pancreas kidney (SPK) transplant patients receiving tacrolimus and mycophenolate mofetil immunosuppression [abstract]. Transplantation 2000; 69: S206. 23. Kaufman DB, Leventhal JR, Koffron A, et al. Simultaneous pancreaskidney transplantation in the mycophenolate mofetil/tacrolimus era: evolution from induction therapy with bladder drainage to noninduction therapy with enteric drainage. Surgery 2000; 128: 726. 24. Rasaiah SB, Light JA, Saski TM, et al. A comparison of daclizumab to ATGAM induction in simultaneous pancreas-kidney transplant recipients on triple maintenance immunosuppression. Clin Transplant 2000; 14: 409. 25. Golconda MS, Rayhill SC, Hunsicker LG. A low rate of acute rejection in simultaneous pancreas-kidney transplant recipients receiving daclizumab induction. [abstract]. Am J Transplant 2001; 1: 320 (A 737). 26. Van der Werf WJ, Reed AI, Hemming AW, et al. Two doses of daclizumab provides effective induction for simultaneous pancreas and kidney transplantation. Am J Transplant 2001; 1: 430 (A 1165). 27. Rehman LU, Atkinson RC, Minich PJ. Two dose daclizumab (Zenapax) is safe and effective induction therapy in adult renal transplantation. Am J Transplant 2001; 1: 300 (A 655).